4D Molecular Therapeutics Inc Cash Flow Reinvestment Rate
4D Molecular Therapeutics Inc cash flow reinvestment rate. 4D Molecular Therapeutics Inc (FDMT) has a Cash Flow Reinvestment Rate of 4.54x as of December 2025, reinvesting $129.55 Million (capex $631.00K plus investments $-128.92 Million) from operating cash flow of $28.55 Million. See financial flexibility index of 4D Molecular Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of 4D Molecular Therapeutics Inc (2017–2017)
Cash flow reinvestment rate of 4D Molecular Therapeutics Inc from 2017 to 2017. Historical reinvestment intensity for 4D Molecular Therapeutics Inc across 1 annual periods. Explore 4D Molecular Therapeutics Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
4D Molecular Therapeutics Inc Cash Flow Reinvestment Rate by Year (2017–2017)
4D Molecular Therapeutics Inc cash flow reinvestment rate by year from 2017 to 2017. Year-by-year capital reinvestment analysis for 4D Molecular Therapeutics Inc. For the full cash flow conversion analysis, see 4D Molecular Therapeutics Inc (FDMT) cash conversion ratio.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2017 | 1.07x | $8.80 Million | $8.24 Million | $573.00K | — |